Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ATAI Life Sciences N.V. ATAI

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Pharma ready to proceed with Phase 2 clinical trial of...read more

FSD Pharma Files Investigational New Drug Application “IND”

   rate and reply

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

   rate and reply

Lucid-MS for Multiple Sclerosis Treatment

  rate and reply

"Julia Levy Award" Recipient David Allan and Dr. John McGraw

   rate and reply

FSD Pharma Inc: Lucid MS Video

FSD Pharma is delighted to announce pre-clinical findings...read more

FSD: Cancellation of Certain Shares Issued to Former CEO

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)...read more

FSD Pharma Issues Corporate Updates

FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to...read more

Atai Life Sciences Increases IPO To $225 Million

Atai Life Sciences late last night announced the pricing of its upsized initial public offering. The clinical-stage biotech firm now expects its IPO to raise gross proceeds of roughly $225.0 million...read more